Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Revitalizing psychiatric drug discovery

Nature Reviews Drug Discovery volume 11, pages 423–424 (2012)Cite this article

Subjects

Abstract

Psychiatric drug discovery needs to close the systems neuroscience gap to improve the clinical success rates of candidate drugs with novel mechanisms of action.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Potter, D. et al. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr. Bull. 32, 692–700 (2006).

    Article  Google Scholar 

  2. Leiser, S. C. et al. A cog in cognition: how the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol. Ther. 122, 302–311 (2009).

    Article  CAS  Google Scholar 

  3. Akil, H. et al. Medicine. The future of psychiatric research: genomes and neural circuits. Science 327, 1580–1581 (2010).

    Article  Google Scholar 

  4. Tye, K. M. & Deisseroth, K. Optogenetic investigation of neural circuits underlying brain disease in animal models. Nature Rev. Neurosci. 13, 251–266 (2012).

    Article  CAS  Google Scholar 

  5. Cuthbert, N. & Insel, T. R. Toward new approaches to psychotic disorders: the NIMH Research Domain Criteria Project. Schizophr. Bull. 36, 1061–1062 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Martin Sarter is at the Department of Psychology, University of Michigan, 530 Church Street, 4032 East Hall, Ann Arbor, Michigan 48103-8862, USA.,

    Martin Sarter

  2. Mark Tricklebank is at the Lilly Centre for Cognitive Neuroscience, Eli Lilly and Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.,

    Mark Tricklebank

Authors
  1. Martin Sarter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Tricklebank
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Martin Sarter or Mark Tricklebank.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary information Figure S1

Conventional and psychobiological target definitions. (PDF 263 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarter, M., Tricklebank, M. Revitalizing psychiatric drug discovery. Nat Rev Drug Discov 11, 423–424 (2012). https://doi.org/10.1038/nrd3755

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3755

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research